

DAFTAR PUSTAKA

- Affandi M, Effendy E, Loebis B, Husada M.S, Nasution N.M.2020.*The Difference Scores Of Positive And Negative Syndrome Scale Exited Components In Psychotic Agitation Patients Of Haloperidol Injection And Those Prescribed With The Injection Of Haloperidol And Diazepam.*Maced J Med Sci. 2020 Jun 30; 8(B):631-636.
- Amir N.2018.Skizofrenia dalam Buku Ajar Psikiatri.Badan Penerbit Fakultas Kedokteran Universitas Indonesia.Jakarta.
- American Psychiatric Association. 2010. *Practice Guideline For The Treatment Of Patient With Schizophrenia* second edition. <http://www.appi.org/CustomService/Pages/Permissions.aspx>
- American Psychiatric Association. 2021.*The American psychiatric Association Guideline for treatment of Patient with skizofrenia.* <https://ajp.psychiatryonline.org> > appi.ajp.177901.
- Arozal W.et.al.2019. *Treatment Pattern Of Antipsychotics And Clinical Features For Treating Patients With Schizophrenia At The Teaching Hospital In Jakarta, Indonesia.*Journal of Applied Pharmaceutical Science 9 (02):2019:057-063.
- Barnes T.R.E and Braude W.M.2004. *Persistent Akathisia Associated With Early Tardive Dyskinesia.* <http://pmj.bmj.com/> on September 11, 2016.
- Bhagwan S. et.al, 2020. *Reversible Syndrome Of Extrapryramidal Movement Disorders With Bilateral Basal Ganglia Lesions In Uremia.*
- Bhowmick,S.et.al,2020.*Movement Disorder And Renal Disease.* <https://doi.org/10.1002/mdc3.13005>.
- Burkhard P et.al.2019.*Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration.*doi: 10.1001/archneur.60.4.521.
- Carnahan RM, Lund BC, Perry PJ, Chrischilles EA.2005 *Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.* Acta Psychiatr Scand 2006; 113: 135–141.
- Cahaya N.et.al.2020. *Deskriptive Study Of Two Antipsychoticscombination And Parkinsonism Syndrome In Paranoid Schizophrenia Treatment.* Current Pharmaceutical Sciences.Vol 4 No.1.

- Cheung,P.Schweitzr,1996.*Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia*.doi: 10.1097/00004850-199612000-00004.
- Cheung,P.Schweitzr,1998. *Correlates of Aggressive Behaviour in Schizophrenia*.
<https://doi.org/10.3109/00048679809065534>.
- Chirchiglia,D.2019.*A discussion of new-onset extrapyramidal syndrome without tremor and neuroimaging signs of encephalopathy following hepatic cirrhosis*.<https://doi.org/10.1016/j.inat.2019.04.010>.
- Chong,S.A.et.al.2003.*Clinical Characteristics And Associated Factors In Antipsychotic-Induced Akathisia Of Asian Patients With Schizophrenia*.DOI: 10.1016/s0920-9964(02)00156-1.
- Chouinard C.1984. *The Extrapyramidal Symptom Rating Scale*. Canadian Journal Neurological science. Volume 7 p 233-244.
- Chouinard C, Margolese H.2005. *Manual for the Extrapyramidal Symptom Rating Scale (ESRS)*. Schizophrenia Research 76 (2005) 247–265.
- Divac N, Milica I, Jakovcevski, Natasa C. 2013. *Second Generation Antipsychotics and Extrapyramidal Adverse Effects*. BioMed Research International Volume 2014, Article ID 656370
- Hasni.D.et.al.2019. *Gambaran Sindrom Ekstrapiramidal Pada Pasien Skizofrenia yang Mendapat Terapi Antipsikotik*.Jurnal Kedokteran 27 (3): 090-094.
- Hirano Y.2018. *Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy: A Study Based on Large-Scale Japanese Claims Data*. Therapeutic Innovation & Regulatory Science XX(X).
- Høiberg MP, Nielsen B.2006. *Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients*. Nord J Psychiatry;60:207;212. Oslo. ISSN 0803-9488.
- Honer WG. *First episode psychosis with extrapyramidal signs prior to antipsychotic drug treatment*.Chinese Sci Bull, 2011 56: 3361–3371, doi: 10.1007/s11434-011-4738-y
- Irma,F.2012. *Penentuan Validitas Dan Reliabilitas Instrumen Prince Henry Hospital Akathisia Rating Scale Versi Bahasa Indonesia*.Universitas Indonesia
- Joubert F-P, Chiliza B, Emsley R, Asmal L.2021. *Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate*. S Afr J Psychiat. 2021;27(0), a1568.

- Kasten.M ,et.al.2011. *Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility*. *Psychopharmacology* (2011) 214:729–736.
- Kluge, C.et.al.2012. *Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons*. *Schizophrenia Bulletin* vol. 38 no. 1 pp. 167–177. Maryland,USA.
- Konsil Kedokteran Indonesia.2006. *Manual rekam Medis*.Jakarta
- Lomba.O.P.et.al.2019. *Risk Assessment And Prediction Of TD Incidence In Psychiatric Patients Taking Concomitant Antipsychotics: A Retrospective Data Analysis*. <https://doi.org/10.1186/s12883-019-1385-4>.
- Misdravi David.2020. *Extrapyramidal Side Effects Of Antipsychotics: Prevalence And Risk Factors. Results From The National FACE-SZ Cohort Cover Title Extrapyramidal Side Effects And Antipsychotics*. *The Journal of clinical psychiatry*, 2019, 80 (1), 10.4088/JCP.18m12246. hal-02473295.
- Monteleone P,et al (2020). *Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the “real-life”*. *Progress in Neuropsychopharmacology & Biological Psychiatry* 109 (2021) 110250.
- Musco,S. et.al. 2019. *Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy*. *Journal of Clinical Psychopharmacology* volume 39, Number 4.
- Naser.D.A.et.al.2021. *Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors*. DOI: 10.2174/1745017902117010001, 2021, 17, 1-7.
- Park S.C et.al.2020. *Relationship Between Body Mass Index And Extrapyramidal Symptoms In Asian Patients With Schizophrenia: The Research On Asian Psychotropic Prescription Patterns For Antipsychotics (Reap-AP)*. *Psychiatria Danubina*, 2020; Vol. 32, No. 2, pp 176-186 <https://doi.org/10.24869/psyd.2020.176>
- Plesnicar B.K.2006. *The Influence Of The CYP2D6 Polymorphism On Psychopathological And Extrapyramidal Symptoms In The Patients On Long-Term Antipsychotic Treatment*.*Journal of Psychopharmacology* 20 (6) 829-833.

- Pringsheim,T.et.al.2018.*Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis.*
- Pusat data dan Informasi Kesehatan Kemenkes.2019. *Situasi Kesehatan Jiwa Di Indonesia.* Jakarta.Infodatin Kemenkes.
- Ribeiro SB,et.al.2016. *Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics.* Eur J Clin Pharmacol (2017) 73:351–355.
- Rolter,B.,Pigato,G.,Antonini,A. 2020. *Prevalence of Extrapyramidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism.* Front. Neurol. 11:593143.
- Ronchetti G. and Scigliano G.2013. *Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis.* CNS Drugs (2013) 27:249–257 DOI 10.1007/s40263-013-0054-1.
- RSJD dr.RM Soedjarwadi,2020. *Hospital Profile* RSJD dr.RM Soedjarwadi.Klaten.
- Sadock BJ, Sadock VA, Pedro Ruiz.2014. *Kaplan & Sadock’s comprehensive textbook of psychiatry (11th ed).* Lippincott Williams & Wilkins.Philadelphia.USA.
- Sadock BJ, Sadock VA.2017. *Kaplan & Sadock’s comprehensive textbook of psychiatry.* Lippincott Williams & Wilkins.Philadelphia.USA.
- Sachdev P. *Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.* Australian and New Zealand Journal of Psychiatry 2004; 38:445–449.
- Schillevoort I, et.al.2001. *Risk of Extrapyramidal Syndromes with Haloperidol, Risperidone, or Olanzapine.* The Annals of Pharmacotherapy.
- Smita.B,Suzaan M,Bhupendra.B,Iqbal B.A.2018.*Reversible Syndrome Of Extrapyramidal Movement Disorders With Bilateral Basal Ganglia Lesions In Uremia.* African Journal of Neurological Sciences.Vol 37.No.1
- Stahl SM.2013. *Stahl’s Essential Psychopharmacology.* Cambridge University Press, New York.

- Steinert.T, Hamman K,2012. *External Validity of Studies on Aggressive Behavior in Patients with Schizophrenia: Systematic Review. Clinical Practice & Epidemiology in Mental Health* Vol 8, 74-80.
- Sugiyono. 2013. *Metode Penelitian Kuantitatif dan Kualitatif dan R&D*.Alfabetha.Bandung.
- Susilowati S.2005. *Penyidikan Efek Samping Haloperidol Dan Chlorpromazine : Studi Kasus Pada Pasien Rawat Inap Di RSJD Dr. Amino Gondho Hutomo Semarang Periode 2005*. Universitas Wahid hasyim Semarang.
- Tenback D,et al.2010. *Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia*. *Journal of Psychopharmacology*. 24(7) (2010) 1031–1035.
- Tim Riskedas Jawa Tengah.2018. *Laporan provinsi Jawa Tengan Riskedas Tahun 2018*.Lembaga Penerbit Badan litbang Kesehatan.Jakarta.
- Weng J, Zhang Y, Li H, et al. 2019. *Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia*. *General Psychiatry*;32:e100026. doi:10.1136/ gpsych-2018-100026
- Whalen K. *Lippincott's Illustrated Review Phammacology 5th ed*. Baltimore, MD : Wolters Kluwer Health/Lippincott Williams & Wilkins.
- Wilianto Y, Yulistiani. 2019. *Side Effects of Antipsychotics on Schizophrenia Patients : A Literature Review*. *Pharmaceutical Journal Of Indonesia* 2019. 4(2): 35-44
- Zhornitsky S, et al.2011. *Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia*. The Royal Australian and New Zealand College of Psychiatrists.